Go to content
UR Home

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy

URN to cite this document:
DOI to cite this document:
Gerthofer, Valeria ; Scheiter, Alexander ; Lüke, Florian ; Keil, Felix ; Utpatel, Kirsten ; Pöhmerer, Laura-Maria-Giovanna ; Seitz, Johannes ; Niessen, Christoph ; Ignatov, Atanas ; Dietmaier, Wolfgang ; Calvisi, Diego F. ; Evert, Matthias ; Ortmann, Olaf ; Seitz, Stephan
Date of publication of this fulltext: 19 Jan 2022 16:00


ALK fusions were first described by Morris et al1 in 1994. Several studies have reported genetic alterations of the ALK gene in various tumor types since then, consisting of mutations, amplifications, and fusions.1-3 Fusion proteins have an active C-terminal tyrosine kinase domain in common.3 Here, we describe an STRN-ALK fusion in malignant peritoneal mesothelioma (MPM), which has previously ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -5707

Contact persons